Equity Briefing : Cel-Sci's CEO Kersten sounds bullish on Multikine® Phase III trial progress

In a newly broadcast radio interview with Eric Michaels of the eHealth Radio Network, Cel-Sci Corporation's (AMEX:CVM) CEO, Geert Kersten hints that Phase III clinical trials for CEL-SCI's lead investigational therapy, Multikine® (Leukocyte Interleukin, Injection), an immunotherapeutic agent being developed as a potential first-line treatment for advanced primary head and neck cancer, is performing well...

In a newly broadcast radio interview with Eric Michaels of the eHealth Radio Network, Cel-Sci Corporation's (AMEX:CVM) CEO, Geert Kersten hints that Phase III clinical trials for CEL-SCI's lead investigational therapy, Multikine® (Leukocyte Interleukin, Injection), an immunotherapeutic agent being developed as a potential first-line treatment for advanced primary head and neck cancer, is performing well.

"Our drug essentially replicates a healthy immune system, and based on everything that we've seen in the clinic so far, if we continue to see the same results, we will have the first non-toxic cancer therapy, explains Kersten. "Think about that, that doesn't exist today."

Among some of the topics of interest to investors which were discussed during the nationally syndicated medical program which can be heard on a number of public radio and HD Radio stations, including XM channel 123, Kersten is asked why it has taken decades for this drug cancer treatment candidate to make its way through the regulatory process and what his vision for the product is at this point in the clinical testing process.

Kersten also reveals new details about the National Institute of Health's interest and role in the current trial and says that his firm plans to expand the trial into additional countries.

"This is the biggest Phase III study ever done in head and neck cancer," Kersten says. "It is being done in eight countries on three continents and we're expanding it to twelve countries, and this one study is designed in one fail swoop to give us approval anywhere and everywhere in the world."

Source: http://bit.ly/MTLNhR

Copyright Thomson Reuters


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: %s via Thomson Reuters ONE


[HUG#1622405]